Lake Street raised the firm’s price target on Beta Bionics (BBNX) to $40 from $35 and keeps a Buy rating on the shares. The firm would be buyers of weakness on what is likely an adverse share reaction to new patient starts being slightly lower than anticipated, stating that NPS was “still solid” at up 37% year-over-year. The firm, which expects the company to introduce 2026 guidance with Q4 results in February, believes continued execution and product development catalysts will support incremental share upside.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics downgraded to Neutral from Buy at BofA
- Premium Valuation and Slowing New Patient Growth Drive Shift to Neutral on Beta Bionics
- Beta Bionics sees Q4 revenue at least $32M, consensus $28.19M
- Beta Bionics price target raised to $33 from $30 at BofA
- Beta Bionics price target raised to $37 from $32 at Truist